A Novel Approach to Leveraging the Microbiome Organ

Alison Lawton has served as Kaleido’s Chief Executive Officer, President and as a member of the Board of Directors since August 2018, after initially joining the company as President and Chief Operating Officer in December 2017. Ms. Lawton has more than 30 years of experience in a range of executive and operating roles in the biopharmaceutical industry. Prior to joining Kaleido, she was COO at Aura Biosciences, and previously held the same role at X4 Pharmaceuticals and OvaScience. Ms. Lawton spent more than 20 years at Genzyme Corporation and subsequently at Sanofi following its acquisition of Genzyme. She served as Senior Vice President and General Manager of Sanofi Biosurgery, a $750 million business that included surgical, orthopedics, and cell therapy and regenerative medicine franchises. Earlier, as SVP of Global Market Access for Genzyme, Ms. Lawton led global functional organizations, including regulatory affairs and quality systems, public policy, health outcomes and strategic pricing, product safety and risk management. Additionally, Ms. Lawton worked for seven years in the U.K. at Warner-Lambert/Parke-Davis. She previously served two terms as the industry representative on the Food & Drug Administration’s Cell & Gene Therapy Advisory Committee and as Chairman of the Board of the Regulatory Affairs Professional Society (RAPS). She is currently an independent Director of ProQR Therapeutics and Verastem, Inc., and was previously a director on the boards of Cubist Pharmaceuticals, CoLucid Pharmaceuticals, and Magenta Therapeutics. Ms. Lawton earned her Bachelor of Science degree in Pharmacology from King’s College London.

Joshua Brumm has served as Kaleido's Chief Operating Officer and Chief Financial Officer since August 2018, and as our Chief Financial Officer since April 2018. Prior to joining Kaleido, Mr. Brumm was COO and CFO at Versartis, where he oversaw the company’s financial strategy, including the successful completion of its initial public offering, played an integral role in product strategy, and helped negotiate the company’s first product partnership. Prior to that, he was executive vice president of finance and principal financial officer at Pharmacyclics, and CFO at ZELTIQ Aesthetics, where he also served in corporate development and sales roles. He also was director of finance at Proteolix, Inc., helping in the sale of the company to Onyx Pharmaceuticals. Over the course of his career, Mr. Brumm has raised more than $800 million in capital. In 2014, he was named Silicon Valley Business Journal’s CFO of the Year for companies under $500 million. He also held investment banking roles at Citigroup Global Markets, Inc. and Morgan Stanley. He holds a B.A. in Business Administration from the University of Notre Dame.

Katharine Knobil joined Kaleido in December 2018 as Chief Medical Officer and Head of Research & Development. Dr. Knobil spent more than 20 years in roles of increasing responsibility at GlaxoSmithKline (GSK), most recently serving as chief medical officer, overseeing medical affairs, health outcomes, global clinical safety and medical governance across the pharmaceutical, vaccines, and consumer businesses. Previously she was CMO for Pharmaceuticals at GSK from 2015 to 2017, and prior to that was senior vice president, value evidence and outcomes. Dr. Knobil first joined GSK in 1997 as a research physician in respiratory clinical development, and subsequently held a number of roles, including leading the European respiratory clinical team, and building the late-stage clinical development for all therapeutic areas in China. Dr. Knobil was recently named one of 2018's Fiercest Women in Life Sciences by FiercePharma. She has served on the Board of Directors of the National Health Council and has been active with the National Academies of Sciences, Engineering, and Medicine, and the Patient Centered Outcomes Research Institute. Dr. Knobil received her B.A. from Cornell University, her M.D. from University of Texas Southwestern Medical School, and completed a Fellowship in Pulmonary and Critical Care Medicine at the Johns Hopkins Medical School.

Michael Bruce, Ph.D. has served as Kaleido's Senior Vice President, Development Operations since August 2018, and previously served as our Senior Vice President, Program, Portfolio, Alliance Management from October 2017 to August 2018. Prior to joining Kaleido, Dr. Bruce served as Senior Vice President, Portfolio Project and Alliance Management at CRISPR Therapeutics from 2015 to 2017. There, he played key roles in building alliances with major biotech and pharmaceutical companies, including acting as Head of Operations of Casebia, a joint venture of CRISPR Therapeutics and Bayer AG. Before joining CRISPR, Dr. Bruce held multiple roles at Pfizer, Inc. and Wyeth from 2003 to 2015, until ultimately serving as Vice President, Development Operations, Worldwide Research and Development. Dr. Bruce holds a B.A. in chemistry from Williams College and a Ph.D. in chemistry from Stanford University.

John Davies, Ph.D. has served as Kaleido's Chief Technology Officer since October 2017. Prior to joining Kaleido, Dr. Davies served as Executive Director, Global Head of In Silico Lead Discovery at Novartis Institutes for Biomedical Research (NIBR), the innovation arm of Novartis AG, from 2012 to 2017. Before that, he held various research positions at NIBR from 1997 to 2012. Earlier in his career, he worked in computational modeling and research at both GlaxoSmithKline and Sandoz. Dr. Davies received his Ph.D. in synthetic organic chemistry from University College London and his B.Sc. in chemistry from the University of East London.

Dr. Miller oversees the consumer product research and development pipeline at Kaleido, following a successful 30 year career at Abbott Nutrition. Miller was responsible for global pediatric, adult, and performance nutrition product development, innovation, new ventures, medical safety, clinical and preclinical research as the Divisional Vice President of R&D, Scientific and Medical Affairs at Abbott Nutrition, and was part of the Executive team managing the $7 billion nutrition business. He was an architect of the global expansion of Abbott Nutrition, establishing R&D Centers in Singapore, Shanghai, China and Bangalore, India. Dr. Miller was co-chair of the Abbott Scientific Governing Board from 2013-2016, overseeing talent development and program efforts of Abbott’s 2,500 scientists for all Abbott Laboratories divisions. He continues to develop leadership potential in scientists through his responsibilities as a Commissioner for the Food Systems Leadership Institute part of the Association of Public and Land Grant Universities. Miller holds a Ph.D. in Nutritional Biochemistry from the University of Wisconsin-Madison, and completed a Staff fellowship at the National Institute of Health.

Wendy Arnold has served as Kaleido's Senior Vice President, Human Resources since January 2018. Ms. Arnold brings more than 20 years of experience in human resources to Kaleido, including extensive work in the biopharmaceutical industry. Prior to joining Kaleido, Ms. Arnold was head of the HR business partnership function at Moderna Therapeutics, and helped lead the HR organization during a period of significant growth, including implementing talent and engagement initiatives, compensation framework and benefits program enhancements. Prior to that, she was at Celgene Avilomics Research (formerly Avila Therapeutics) where she was responsible for building and developing the HR infrastructure for the company’s early research and development division. She also held senior HR positions at Inotek Pharmaceuticals and Amylin Pharmaceuticals. Ms. Arnold received her Bachelor of Science degree from Colorado State University.

Susan Stewart has served as Kaleido's Senior Vice President, Regulatory Affairs & Quality since April 2018. Ms. Stewart has worked for more than 25 years in biopharmaceutical regulatory affairs, with significant experience devising innovative strategies for novel therapeutics, overseeing regulatory submissions at various stages of product development and leading interactions with global health authorities. Previously, in addition to being an independent regulatory consultant for several years, she was senior vice president of regulatory affairs, quality, and compliance at Tokai Pharmaceuticals and vice president, regulatory affairs at Transmolecular. She also spent more than 10 years at Genzyme Corporation in regulatory and compliance roles, including serving as vice president, regulatory affairs. She received her J.D. from Concord Law School at Purdue University Global and her B.A. from the University of Massachusetts.

Stephen Sofen, Ph.D. has served as Kaleido's Senior Vice President, Technical Operations since March 2018. Dr. Sofen brings to Kaleido extensive experience in technical innovation, product development and manufacturing, including more than 15 years in the biotechnology industry. Most recently, he was a vice president of technical operations at CRISPR Therapeutics, where he built and led the company’s process development, analytical sciences and manufacturing capabilities. Dr. Sofen also held senior technology and operations positions at Biogen, Genzyme Corporation and the Novartis-MIT Center for Continuous Manufacturing. He received his Ph.D. in bioinorganic chemistry from University of California, Berkley and his B.A. from Reed College.

Jeffrey Moore has served as Kaleido's Senior Vice President, Finance & Administration since June 2017. Prior to joining Kaleido, he served as Senior Vice President, Finance and Operations and previously as Chief Financial Officer and Treasurer for Axcella Health, Inc., a biotechnology company, from 2011 to 2017. Before that, Mr. Moore served as Chief Financial Officer at Helicos BioSciences Corporation, a life sciences company, from August 2009 to February 2014, and in various other positions at Joule Unlimited Technologies, Inc., BG Medicine, Inc., Affinnova, Inc., and Flagship Ventures. Prior to joining Flagship Ventures, Mr. Moore served as the Director of Business Analysis and Planning at Celera Genomics, and as Vice President, Treasury Operations and Chief Accounting Officer at PerSeptive Biosystems. Mr. Moore started his career with Price Waterhouse in its emerging growth company practice. Mr. Moore received his B.S. degree from Cornell University and an M.B.A. degree from Vanderbilt University.